Deferasirox, also known as Exjade, is an iron chelator developed by Novartis, a Swiss pharmaceutical company. Here is a detailed introduction to Deferasirox:
Basic Information
English Name: Deferasirox
Alternative Names: Exjade, Deferasirox-D4, etc.
CAS Number: 201530-41-8
Chemical Formula: C21H15N3O4
Molecular Weight: 373.362 g/mol
Density: 1.472 g/cm³ (or predicted as 1.4±0.1 g/cm³)
Melting Point: 260-262ºC
Boiling Point: 651ºC (or predicted as 672.1±65.0 °C)
Flash Point: 347.5ºC (or predicted as 360.3±34.3 °C)
Refractive Index: 1.699
Pharmacological Action
Deferasirox is an orally active chelator that exhibits high selectivity for iron (Fe³⁺), binding to it with a high affinity in a 2:1 ratio. It significantly reduces iron overload in the heart and liver and has demonstrated good safety and tolerability profiles. Additionally, Deferasirox possesses antifungal (against fungi growing in iron-rich environments such as mucormycosis), antiproliferative, antimalarial, antioxidant stress injury, and anti-cytotoxic-induced apoptosis properties.
Indications
Deferasirox is used to treat patients with chronic iron overload due to blood transfusions and iron overload in patients with thalassemia. In Europe, it is recommended as a first-line treatment for iron overload in patients with thalassemia aged 6 years and older. In China, Deferasirox is currently undergoing clinical research.
Storage Conditions
Deferasirox should be stored in a cool, light-protected area to maintain its stability and effectiveness.
